medigraphic.com
ISSN 2305-7939 (Electronic)

2019, Number 2

<< Back Next >>

RCU 2019; 8 (2)

Prostatic transglutaminase: The future of the diagnosis and treatment of prostate cancer

Piamo MAJ, García RMA

Language: Spanish
References: 18
Page: 187-193
PDF size: 859.29 Kb.


ABSTRACT

Introduction: Prostatic transglutaminase is a protein with an exclusive expression in the prostate. Even though its function has not been fully clarified, there are many studies on its implications in processes such as the aggressiveness of cancer cells. Current knowledge on it allows setting hypotheses for new and more advanced researches in this field. Objective: To describe the biochemical aspects and clinical implications of prostatic transglutaminase. Methods: A search was made in the national and international literature in English and Spanish through some databases as MEDLINE/PubMed, ELSEVIER, SciELO, EBSCO, Hinari and Google Schcolar. There were consulted a total of 29 documents that were published between 2003 and 2018. Conclusions: The prostate-restricted expression of prostatic transglutaminase raises the possibility of a new target for prostate cancer.


REFERENCES

  1. Berlin A, Fernández M. Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales. Rev Med Chile 2015 [citado 15/12/2018]; 143: 223-36. Disponible en: https://scielo.conicyt.cl/pdf/rmc/v143n2/art10. pdf

  2. Boletín de Información Técnica Especializada de la Cuenta de Alto Costo. Bogotá. 2017;3(12).

  3. Onyekachi Odii Benedict, Coussons Peter. Biological Functionalities of Transglutaminase 2 and the Possibility of Its Compensation by Other Members of the Transglutaminase Family. The Scientific World Journal. 2014 [citado 15/12/2018]; Article ID714561, 13 pages. Disponible en: http://downloads.hindawi.com/journals/tswj/2 014/714561.pdf

  4. Iismaa SE. The prostate-specific protein, transglutaminase 4 (TG4), is an autoantigen associated with male subfertility. Ann Transl Med. [citado 15/12/2018];4 (Suppl 1):S35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5104643/. http://atm.amegroups.com/article/view/12225 /pdf

  5. Ablin Richard J, Owen Sioned, Jiang Wen. Prostate transglutaminase (TGase-4) induces epithelial-to-mesenchymal transition in prostate cancer cells. Anticancer Research 2017 [citado 15/12/2018]; 37 (2):481-88. Disponible en: http://orca.cf.ac.uk/98176/1/Ablin%20et%20al %20TGase4%20%23AR%202017%20reprint.pdf

  6. Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Transglutaminase regulation of cell function. Physiol Rev. 2014 [citado 15/12/2018]; Apr;94(2):383-417. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C4044299/

  7. Landegren N, Sharon D, Shum AK, Khan IS, Fasano KJ, Hallgren A, et al. Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci. Transl. Med. 2015 [citado 15/12/2018]. Disponible en: http://stm.sciencemag.org/content/scitransme d/7/292/292ra101.full.pdf

  8. National Center for Biotechnology Information, US National Library of Medicine. TGM4 transglutaminase 4. Gene ID: 7047. 2019. [citado 10/02/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/gene?Db=gene& Cmd=DetailsSearch&Term=7047

  9. Un G, Meka CS, Bright SP, Veltri RW. Gen de la transglutaminasa prostático específico humano: promotor clonación, expresión específica de tejido y la regulación por disminución en el cáncer de próstata metastásico. Urology. 1999 [citado 10/02/2019]; 54:1105-11 Disponible en: https://dialnet.unirioja.es/descarga/articulo/41 16663.pdf

  10. An G, Meka CS, Bright SP, Veltri RW. Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology. 1999 [citado 10/02/2019]; 54:1105-11. Disponible en: https://dialnet.unirioja.es/descarga/articulo/41 16663.pdf

  11. Jiang WG, Ablin RJ, Kynaston HG, Mason MD: Expression of the prostate type transglutaminase (TGase-4) in clinical prostate cancer (Abstract). Presented at: American Association for Cancer Research, 98th Annual Meeting. Los Angeles, CA, USA; 2007:14-8.

  12. Jiang WG, Ye L, Ablin RJ, Kynaston HG, Mason MD: The prostate transglutaminase, TGase-4, coordinates with the HGFL/ MSP-RON system in stimulating the migration of prostate cancer cells. Int. J. Oncol [citado 10/02/2019]; 2010; 37:413-18. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/205966 68

  13. Jiang WG, Abliln RJ, Mason MD. The impact of prostate transglutaminase (TGase-4) on the micromotion of prostate cancer cells. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA. 2010:5-7. [citado 10/02/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/273125 84

  14. Jiang WG, Ablin R: Expression of transglutaminase in human prostate cancer cells and the role in motogen induced migration and matrix adhesion. FASEB J. 2003;17: C288. [citado 10/02/2019]. Disponible en: https://translationalmedicine. biomedcentral.com/.../14

  15. Zhu ML and Kyprianou N: Role of androgens and the androgen receptor in epithelialmesenchymal transition and invasion of prostate cancer cells. FASEB J 24: 2010: 769-77. [citado 10/02/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/199010 20

  16. Alonso-Varona A, Palomares T, Bilbao P, Calle Y, Castro B, Barberá-Guillem E: Tumor-host interaction in non-random metastatic pattern distribution. Bull. Cancer. 1996 [citado 10/02/2019]; 83:27-38. Disponible en: https://www.karger.com/Article/Abstract/7322

  17. Iiizumi M, Mohinta S, Bandyopadhyay S, Watabe K: Tumor endothelial cell interactions: therapeutic potential. Microvasc. Res. 2007 [citado 10/02/2019]. 4:114-120. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/174987 48

  18. Jiang WG, Ablin RJ, Kynaston HG, Mason MD: The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc. Res 2009. 77:150-7.




2020     |     www.medigraphic.com